High-rolling investors have positioned themselves bullish on Recursion Pharmaceuticals (NASDAQ:RXRX), and it's important for retail traders to take note. \This activity came to our attention today ...

Recursion RXRX is slated to report first-quarter 2024 results on May 9, after market close. The Zacks Consensus Estimate is pegged at a loss of 43 cents per share. The Zacks Consensus Estimate for ...

As many veteran investors can attest, biotech stocks are tricky to trade. Their potential upside is enormous, but so is their risk. Too many of these names end up being complete busts. If you pick the ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to beat earnings when it reports second-quarter 2025 results on Aug. 5 ...

Chris Gibson, Cofounder and CEO of Recursion, lays out how his company is building the biological data, and layering on AI, to assist in the development of new, effective therapeutics.

Recursion on Tuesday announces top-line results of the SYCAMORE trial, studying REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, but there were not yet ...

Everything touching artificial intelligence (AI) is hot right now, so it's no surprise that the biotech Recursion Pharmaceuticals (NASDAQ: RXRX) could be positioned to ride the ongoing wave of hype to ...

SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a next-gen biopharma company combining automated, experimental biology with artificial intelligence to discover and develop drugs at scale, today announced ...

We recently published a list of the 12 Best AI Stocks to Invest in According to Reddit. In this article, we are going to take a look at where Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stands ...

Recursion Pharma’s May update is the primary near-term driver of its stock. The company ended 2024 with $60M in cash, providing runway till 2027. Up Next: Wall Street trader’s 34-0 strategy goes ...